P2X7受体拮抗剂市场：按药物、应用和地区划分

据估计，P2x7 受体拮抗剂市场在 2026 年的价值为 1.352 亿美元，预计到 2033 年将达到 4.38 亿美元，从 2026 年到 2033 年的复合年增长率为 18.3%。

P2X7受体拮抗剂仍处于研发阶段，需要获得监管部门核准才能上市。製造商必须向美国食品药物管理局（FDA）提交新药临床实验申请（IND）。所有药物都必须经过FDA制定的核准流程。与其他新药一样，P2X7受体拮抗剂在提交新药临床实验申请（IND）后也需要进行临床试验。然而，由于严格的监管核准流程，製药公司在将这些药物推向市场时面临许多挑战。这些因素被认为是影响全球P2X7受体拮抗剂市场及其成长的因素。

市场动态

由于目前缺乏有效的治疗方法， P2X7受体拮抗剂类药物盈利丰厚。主要企业都在加大对该类药物研发的投入，专利保护可望帮助市场参与者获得高额收益。重度忧郁症、情绪障碍、慢性疼痛和发炎等疾病和症状十分普遍，且发生率呈上升趋势。根据英国国家医疗服务体系数位部门（NHS Digital）的数据显示，2016年抗忧郁症处方笺增幅最大，显示忧郁症的流行趋势。 P2X7受体拮抗剂一旦上市，可望在核准的疾病或适应症领域中占据可观的市场。製药公司也正在透过开发创新药物（例如AKP-23494954/RQ-00466479（旭化成/RaQualia Pharma））来推动P2X7受体拮抗剂类药物的发展。预计这些因素将在预测期内支撑全球P2X7受体拮抗剂市场的成长。

本次调查的主要特点

• 本报告对 P2X7 受体拮抗剂市场进行了详细分析，以 2025 年为基准年，给出了预测期（2026-2033 年）内的市场规模和復合年增长率（%）。
• 它还重点介绍了各个细分市场的潜在商机，并说明了该市场具有吸引力的投资提案矩阵。
• 该研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或核准、区域前景以及主要企业采取的竞争策略的重要见解。
• 该研究根据以下参数对全球 P2X7 受体拮抗剂市场的主要企业进行了分析：公司概况、财务绩效、产品系列、地理扩张、分销策略、关键发展和策略。
• 本报告的研究结果将使负责人和企业经营团队能够透过技术升级、市场扩张和行销策略，为未来的产品发布做出明智的决策。
• 这份全球 P2X7 受体拮抗剂市场报告的目标受众是该行业的各类相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
• 相关人员可以透过各种用于分析 P2X7 受体拮抗剂市场的策略矩阵轻鬆做出决策。

目录

第一章 研究目标与前提条件

• 调查目的
• 先决条件
• 简称

第二章 市场范围

• 报告概述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章 市场动态、监理及趋势分析

• 管道分析
• 市场动态
  • 司机
  • 抑制因素
  • 市场机会
  • 影响分析
• 重大进展
• PEST分析
• 流行病学

4. 2026-2033年全球P2X7受体拮抗剂市场（依药物类型划分）

• AKP-23494954/RQ-00466479
• EVT 401
• GSK1482160
• JNJ-55308942
• JNJ-54175446
• 其他（例如 AZ11657312）

5. 2026-2033年全球P2X7受体拮抗剂市场（依应用领域划分）

• 中枢神经系统疾病
• 免疫系统疾病
• 其他的

6. 2026-2033年全球P2X7受体拮抗剂市场（依地区划分）

• 北美洲
  • 我们
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲国家
• 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 亚太其他地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东国家
• 非洲
  • 南非
  • 北非
  • 中非

第七章 竞争情势

• 公司简介
  • Asahi Kasei Corporation
  • GlaxoSmithKline Plc
  • Johnson &Johnson
  • AstraZeneca Plc
  • Evotec AG
  • RaQualia Pharma

第八章各节

• 参考
• 调查方法

P2x7 Receptor Antagonists Market is estimated to be valued at USD 135.2 Mn in 2026 and is expected to reach USD 438 Mn by 2033, growing at a compound annual growth rate (CAGR) of 18.3% from 2026 to 2033.

P2X7 receptor antagonists are still in the developmental stage and will require regulatory approval for introduction into the market. Manufacturers need to file an Investigational New Drug Application (IND) with the U.S. Food & Drug Application (FDA). Every drug is required to go through the approval process set by the FDA. P2X7 antagonists will be going through all the clinical trials after filing an Investigational New Drug (IND) application as any other new drug. However, the pharmaceutical organizations face several challenges for introducing these medications in the market due to a stringent regulatory approval process. These factors are considered in global P2X7 receptor antagonist market and factors affecting global P2X7 receptor antagonist market growth.

Market Dynamics

P2X7 Receptor Antagonists drug category is highly lucrative, as no drug therapies are available in this category. Leading organizations are investing in research and development of drugs in this category, which is expected to help market players in generating high revenue using patent protection. Disease and conditions such as major depressive disorders, mood disorders, chronic pain, and inflammation are highly prevalent and their incidence is also increasing. According to National Health Service Digital (NHS Digital), U.K., antidepressants medications prescriptions observed the largest increase in 2016, indicating the prevalence of depressive disorders. If launched, P2X7 receptor antagonists will be capable of acquiring a significant amount of market share for the disease or indication for which they have been approved. Drug manufacturers are also advancing the P2X7 antagonist drug category by developing innovative drugs such as AKP-23494954/RQ-00466479 (Asahi Kasei/RaQualia Pharma). These factors are expected to support global P2X7 receptor antagonist market growth over the forecast period.

Key features of the study

• This report provides in-depth analysis of the P2X7 receptor antagonists market and provides market size (USD Mn) and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global P2X7 receptor antagonists market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
• Key companies covered as a part of this study include, Asahi Kasei Corporation, GlaxoSmithKline Plc, Johnson & Johnson, AstraZeneca Plc, Evotec AG, and RaQualia Pharma
• Insights from this report would allow marketers and the management authorities of companies to make informed decisions regarding their future product launches, by technology up-gradation, market expansion, and marketing tactics
• The global P2X7 receptor antagonists market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the P2X7 receptor antagonists market

Market Segmentation

• Drugs Insights (Revenue, USD Mn, 2026 - 2033)
  • AKP-23494954/RQ-00466479
  • EVT 401
  • GSK1482160
  • JNJ-55308942
  • JNJ-54175446
  • Others (e.g.- AZ11657312)
• Application Insights (Revenue, USD Mn, 2026 - 2033)
  • Central Nervous System Disorders
  • Immunological Disorders
  • Others
• Regional Insights (Revenue, USD Mn, 2026 - 2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • AstraZeneca Plc
  • RaQualia Pharma
  • Evotec AG
  • Asahi Kasei Corporation

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drugs
  • Market Snippet, By Application
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Pipeline Analysis
• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
  • Impact Analysis
• Key Developments
• PEST Analysis
• Epidemiology

4. Global P2X7 Receptor Antagonists Market, By Drugs, 2026-2033 (USD Mn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• AKP-23494954/RQ-00466479
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• EVT 401
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• GSK1482160
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• JNJ-55308942
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• JNJ-54175446
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Others (e.g.- AZ11657312)
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

5. Global P2X7 Receptor Antagonists Market, By Application, 2026-2033 (USD Mn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Central Nervous System Disorders
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Immunological Disorders
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Others
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

6. Global P2X7 Receptor Antagonists Market, By Region, 2026-2033 (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 - 2033
• North America
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
  • Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
  • Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
  • Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
  • Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
  • Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033
  • Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
  • Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

7. Competitive Landscape

• Company Profiles
  • Asahi Kasei Corporation
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Evotec AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • RaQualia Pharma
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Section

• References
• Research Methodology
• About us and Sales Contact